Diary - News
All news GAOMA Therapeutics announces its first capital increase and a strategic partnership with the PPRS Group, for the development of its first-in-class drug-candidate GAO-3-02.
Jordan Guyon, GAOMA’s Co-founder and CEO, comments: “GAOMA is proud to have achieved this first financing round, which obviously represents a critical step in the development of the project. Such funding will enable GAOMA to properly structure the company, to enrich its governance and to pursue the preclinical development of its lead program GAO-3-02 in epilepsy”.